Please assess the completion status of the following clinical trial:

Trial Title: Human Amniotic Tissue-derived Allograft, NuCel, in Posteriolateral Lumbar Fusions for Degenerative Disc Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 18 and 75 years~* Symptomatic, single-level degenerative lumbar disc disease, spondylosis or spondylolisthesis~* Failed conservative treatments~* Low risk for non-union~* Must be candidates for single-level, posteriolateral lumbar spine fusion~* Must be able and willing to give Informed Consent~* English-speaking~Exclusion Criteria:~* Smoker (any smoking ≤3 months prior to consent); (Patel et al. 2013)~* Patients with poorly controlled diabetes mellitus (HgbA1c \> 7%)~* Documented osteoporosis~* Prior lumbar spinal surgery at the same spinal level, or immediately adjacent spine level, to the level being operated on~* Back pain due to infection, tumour, or metabolic bone disease~* Terminal disease, such as HIV infection, neoplasm~* Autoimmune disease, such as rheumatoid arthritis~* Morbid obesity (body mass index (BMI) of 35 kg/m2)~* Major psychiatric illness in the last year~* History of alcohol or drug abuse in the last year~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- NuCel (Type: EXPERIMENTAL): Stemcell allograft
- Demineralized Bone Matrix (DBM) (Type: ACTIVE_COMPARATOR): Demineralized Bone Matrix (DBM) bone graft substitute

Based on this trial design, predict the completion outcome and termination type (if applicable).